Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04253704
Other study ID # SYT.P0104-B1.B2
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date February 13, 2017
Est. completion date March 3, 2017

Study information

Verified date January 2020
Source Sytheon Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a placebo-controlled double-blinded trial to compare effects of 2% IDL lotion to placebo in female subjects with dry skin. Primary endpoints were skin hydration (NovaMeter) and transepidermal water loss (VapoMeter).


Description:

1. Objective: To evaluate the efficacy of two topically applied test materials and the ability to increase hydration and decrease the transepidermal water loss of the skin. Efficacy was evaluated instrumentally using the NovaMeter and VapoMeter.

2. Test Material Description: On January 4, 2017, two test samples labeled Hydrating Lotion HydraSynol IDL RC-02-38, 12/21/16 and Hydrating Lotion Control RC-02-38A, 12/21/16 were received from Sytheon Ltd. and assigned CR Lab Nos.: P0104-B1 and P0104-B2, respectively.

3. Test Material Handling: Upon arrival at Cantor Research Laboratories, Inc., the test materials were assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received and tests requested. Samples are retained for a period of three months beyond submission of final report unless otherwise specified by the sponsor or if sample is known to be in support of governmental applications, in which case retained samples are kept two years beyond final report submission. Sample disposal is conducted in compliance with appropriate federal, state and local ordinances.

4. Recruitment: Panel selection was accomplished by advertisements in local periodicals, community bulletin boards, phone solicitation, electronic media or any combination thereof.

5. Informed Consent: In compliance with 21 CFR Ch.1 Part 50, Subpart B, informed consent was obtained from each volunteer prior to the commencement of the study. The consent form described the procedures, possible adverse effects, associated risks, and potential benefits of the study and the limits of liability. Panelists signed and dated the informed consent document to indicate their authorization to proceed and acknowledge their understanding of the contents.

6. NovaMeter: The Novameter is a multifunctional electronic laboratory instrument that measures skin impedance. It is designed to provide non-invasive, objective, reproducible method of measurement to quantify biophysical characteristics and relative hydration of the skin.

7. VapoMeter: The VapoMeter is a fully portable instrument for measureing TEWL (transepidermal water loss) values and evaporation rates. TEWL is an indicator of the skin's barrier function. The core of the VapoMeter is a sensitive humidity sensor that is inside a cylindrical measurement chamber. This chamber is closed by the skin or other measurement surface during the measurement period and is unaffected by ambient airflows. The sensor monitors the increase of relative humidity (RH) inside the chamber during the measurement. The evaporation rate value (g/m²h) is automatically calculated from the RH increase. The chamber is passively ventilated between measurements and the ventilation time is automatically controlled. The VapoMeter is widely accepted and an efficient instrument for TEWL measurements.

8. Washout period: Five days prior to the study the panelists were told to not use any moisturizers or treatment products on their arms and refrain from using any other products during the course of the study. They were asked to wash their arms with only ivory soap and pat dry.

9. Baseline: The panelists arrived at the lab with their arms washed by water alone (if forearm skin was not dry, the panelist was asked to wash their arms with only ivory soap and pat dry). Panelists with Skin Dryness Grade of 6 and 7 were inducted in the study. A trained technician examined the test areas (left and right volar arms) for any abnormalities that would obstruct the measurements. The left arm was used for the test material Hydrating Lotion HydraSynol IDL RC-02-38, 12/21/16 (CR Lab No. P0104-B1). The right arm was used for Hydrating Lotion Control RC-02-38A, 12/21/16 (CR Lab No. P0104-B2). The panelists were required to equilibrate to the controlled environment with a constant temperature of 70 degrees F and humidity of 30% Rh for half hour. Measurements on each arm (left and right volar arms) were taken using the NovaMeter and VapoMeter. A trained technician then applied each test material to the respective volar arm in order for the panelist to observe the manner in which the products should be applied for two weeks. The test materials were allowed to dry before the dismissal of the panelist. The panelists were then given the pre weighed test materials as well as a study diary in order to list the time of each application, the date and any subjective comments that they might have about the test materials.

10. Week 2: The panelists arrived at the lab with their arms applied with the test materials at least five hours prior. A trained technician examined the test areas (left and right volar arms) for any abnormalities that would obstruct the measurements. The panelists were allowed to equilibrate to the controlled environment with a constant temperature of 70 degrees F and humidity of 30% Rh for a half hour. Measurements on each arm (left and right volar arms) were taken again using the NovaMeter and VapoMeter. The test materials were weighed and diaries collected to check for compliance.

11. Day 18 (after 4 days regression): The panelists arrived at the lab. A trained technician examined the test areas (left and right volar arms) for any abnormalities that would obstruct the measurements. The panelists were allowed to equilibrate to the controlled environment with a constant temperature of 70 degrees F and humidity of 30% Rh for a half hour. Measurements on each arm (left and right volar arms) were taken again using the NovaMeter and VapoMeter.

12. Adverse reactions: Subjects were instructed to report any delayed reactions which might occur after the final reading. Clients are notified immediately in the case of an adverse reaction and a determination is made as to a treatment program if necessary.

13. Statistical Analysis: All of the data was tabulated in a Microsoft® Excel spreadsheet. Using the t-Test, the statistical significance of the net change from baseline (pre-application) to each subsequent time point was assessed. Statistical significance was defined at the p=0.05 or less level (corresponding to a 95% or greater confidence level).


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date March 3, 2017
Est. primary completion date March 3, 2017
Accepts healthy volunteers No
Gender Female
Age group 35 Years to 57 Years
Eligibility Inclusion Criteria:

1. Females who were thirty-five to fifty-seven years of age.

2. Individuals free of any dermatological or systemic disorder, which would have interfered with the results, at the discretion of the investigator.

3. Individuals who had completed a preliminary medical history mandated by Cantor Research Laboratories, Inc.

4. Individuals who had read, understood and signed an informed consent document as required by Reference 21 CFR Ch. 1 Part 50, Subpart B. Consent forms are kept on file and are available for examination on the premises of Cantor Research Laboratories, Inc., only.

5. Individuals who had abstained from the use of all moisturizing products for at least one week prior to treatment conditions.

6. Individuals with known dry skin.

Exclusion Criteria:

1. Individuals who were under doctor's care.

2. Individuals who were taking medication, which in the opinion of the investigator would have masked or interfered with the results.

3. Individuals with chronic skin allergies.

4. Females who were pregnant or lactating.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
IDL lotion
IDL lotion is water-based (> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
Control lotion
Control lotion is water-based (> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).

Locations

Country Name City State
United States Cantor Research Laboratory Blauvelt New York

Sponsors (2)

Lead Sponsor Collaborator
Shyla Cantor Sytheon Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Skin Hydration Change in skin hydration (NovaMeter assessment) Days 0, 7, 14 and 18
Primary Transepidermal water loss (TEWL) Change in transepidermal water loss (Vapometer assessment) Days 0, 14 and 18
See also
  Status Clinical Trial Phase
Completed NCT05046015 - Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products N/A
Completed NCT02216526 - Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents N/A
Completed NCT03824886 - Enhancing SKIN Health and Safety in Aged CARE N/A
Completed NCT02557698 - Effectiveness of Using an Oil Bath Additive N/A
Completed NCT03093597 - Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin N/A
Active, not recruiting NCT03815305 - Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2 Phase 4
Recruiting NCT05639933 - Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors Phase 2
Completed NCT06178367 - Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment Phase 3
Completed NCT04127513 - Comparison of 12% Ammonium Lactate and 10% Urea Cream in Geriatric With Xerosis Cutis Phase 3